MorphoSys Highlights Potential of Its Mid- to Late-Stage Onc

EQS-News: MorphoSys AG


/ Key word: Miscellaneous





MorphoSys Highlights Potential of Its Mid- to Late-Stage Oncology Pipeline at 2023 ASCO and EHA Annual Meetings






11.05.2023 / 18:39... | May 11, 2023

Related Keywords

Germany , Illinois , United States , Boston , Massachusetts , Chicago , Planegg , Bayern , American , Julia Neugebauer , Eamonn Nolan , Tim Demuth , Thomas Biegi , Constellation Pharmaceuticals Inc , European Hematology Association , Nasdaq , American Society Of Hematology Annual Meeting , Xencor Inc , American Society Of Clinical Oncology , Drug Administration , Linkedin , Exchange Commission , Development Officer , Twitter , American Association For Cancer Research Annual Meeting , Sys Highlights Potential , Late Stage Oncology Pipeline , American Society , Clinical Oncology , Annual Meeting , Hybrid Congress , Morphosys Chief Research , American Association , Cancer Research Annual Meeting , High Risk Essential Thrombocythemia Refractory , Preliminary Results From , Advanced Solid Tumors , Hematologic Malignancies , Preliminary Phase , Subgroup Analysis , Refractory Diffuse Largeb Cell , Combined With Ruxolitinib , Patients With , Final Results , Antibody Dependent Cell Mediated Cytotoxicity , Antibody Dependent Cellular Phagocytosis , Medication Guide , Prescribing Information , Patient Information , Important Safety , Morphosy Annual Report , Morphosys Ag Stock Exchange , News , Information , Press Release , Morphosys , Key , Highlights , Potential , F , Its , O , Ncology , Pipeline , It , 023 , Disco , End , Ha , Nnual , Eetings Mor De0006632003 ,